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Rational drug-design approach 
supported with thermodynamic 
studies — a peptide leader for the 
efficient bi-substrate inhibitor of 
protein kinase CK2
Maria Winiewska-Szajewska  1,2, Dawid Płonka1, Igor Zhukov1 & Jarosław Poznański  1
Numerous inhibitors of protein kinases act on the basis of competition, targeting the ATP binding 
site. In this work, we present a procedure of rational design of a bi-substrate inhibitor, complemented 
with biophysical assays. The inhibitors of this type are commonly engineered by combining ligands 
carrying an ATP-like part with a peptide or peptide-mimicking fragment that determines specificity. 
Approach presented in this paper led to generation of a specific system for independent screening for 
efficient ligands and peptides, by means of thermodynamic measurements, that assessed the ability 
of the identified ligand and peptide to combine into a bi-substrate inhibitor. The catalytic subunit of 
human protein kinase CK2 was used as the model target. Peptide sequence was optimized using peptide 
libraries [KGDE]-[DE]-[ST]-[DE]3–4-nH2, originated from the consensus CK2 sequence. We identified 
KeSeee-nH2 peptide as the most promising one, whose binding affinity is substantially higher 
than that of the reference RRRDDDSDDD peptide. We assessed its potency to form an efficient bi-
substrate inhibitor using tetrabromobenzotriazole (TBBt) as the model ATP-competitive inhibitor. The 
formation of ternary complex was monitored using Differential Scanning Fluorimetry (DSF), Microscale 
Thermophoresis (MST) and Isothermal Titration Calorimetry (ITC).
Protein kinases catalyze the transfer of the γ-phosphate from ATP to the acceptor group of a specific amino acid 
of a target protein1. Protein kinases are attractive targets in cancer treatment, since the overexpression or muta-
tion of particular kinases has been associated with cancerogenesis2–4. The majority of available protein kinase 
inhibitors act on the basis of competition, targeting the ATP binding site. The structure of the latter is highly 
preserved in various protein kinases, and thus, in spite of their high affinity, the inhibitors of this type may not 
be selective enough for a particular protein kinase. However, in addition to the ATP-binding site, each protein 
kinase has a specific binding site for the target protein(s), which enables the recognition of a so-called consensus 
sequence, identifying residues that preferably flank the phosphorylation acceptor site. This sequence, whose pres-
ence is necessary and sufficient to be recognized by a particular kinase, describes the general target specificity of 
the protein kinase5. Short peptides or peptide-mimetics that block the substrate binding site are therefore another 
group of potentially selective inhibitors of protein kinases6–8. However, due to the nature of kinase interaction 
with a target protein, the ligands of such type, mimicking that interaction, are rather weak binders.
To overcome all those problems and to enhance both the affinity and the specificity, bi-substrate inhibitors 
have been designed9,10. Ligands of this type target simultaneously the ATP- and substrate-binding sites, therefore, 
they should be designed on the basis of the shape and the location of natural substrates9. Such inhibitors are 
usually engineered by coupling ligands targeting ATP-binding site with a peptide fragment that determines the 
specificity11. This concept has been implemented leading to some moderately efficient inhibitors, consisting of a 
peptide fragment conjugated with either adenosine12–15 or nonhydrolyzable ATP derivatives16–18. Alternatively, a 
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peptide may be conjugated with an ATP-competitive inhibitor11,19–22. This concept of the protein kinase inhibitor 
design is very promising, since the combination of two substrates required by the target enzyme may display very 
high specificity23.
However, there are several pitfalls to avoid in the development of new bi-substrate inhibitors. First of all, the 
interaction with the target peptides may be associated with conformational changes occurring in the kinase upon 
ligand binding. This includes global domain movement or local changes in the glycine rich P-loop, C-helix and 
activation loop6,24. Since the ligand-induced conformational changes in the target protein are still difficult to 
predict, we decided to support molecular modeling with experimental thermodynamic studies to identify the 
preferred sequence of the peptide part, and to check experimentally whether possible conformational changes 
interfere with the binding of the ATP-competitive part of a potential bi-substrate inhibitor of CK2α.
CK2 is a pleiotropic kinase that regulates many independent processes in cells because of its ability to phos-
phorylate multiple proteins (until now over 200 substrates of this kinase have been identified)25. Unlike the 
majority of Ser/Thr protein kinases, which recognize basic phosphoacceptor sites, the consensus sequence of 
CK2 displays preference towards acidic residues flanking the phosphate donor. Minimal consensus requires the 
presence of glutamate, aspartate, or occasionally phosphoserine (Sp) or phosphotyrosine (Yp) at the position +3 
relative to the phosphoacceptor site. Although a single acidic residue at this position is sufficient for recognition, 
the presence of multiple acidic amino acids located upstream is strongly preferred. The significance of individual 
residues at a given position depends on the overall peptide sequence. An acidic residue at position +1 is almost 
as important as that at +3, while acidic residue at +2 is rather important for peptides in which no other acidic 
residues are located upstream26,27. Summarizing, the general consensus sequence, most frequently recognized by 
CK2, is X-[ST]-X-X-[EDSpYp]-X, where X is preferably acidic5,26–28.
Although the contribution of protein kinase CK2 to neoplasia formation remains unclear, CK2 has become 
a therapeutic target in anticancer treatments29. As for the most protein kinases, the majority of CK2 inhibitors 
target the ATP-binding site. There are also several reports regarding very promising bi-substrate inhibitors against 
CK230–33. Most of them were designed using a common general approach. Enkvist et al. developed a highly potent 
inhibitor ARC-1502 (Ki = 0.5 nM), a conjugate of 4,5,6,7-tetrabromo-1H-benzimidazole with peptides containing 
multiple aspartic acid residues30, and was very successful in further optimization32. More recently, a bi-substrate 
inhibitor K137-E4 (IC50 = 25 nM), also derived form tetrabromo-1H-benzimidazole, was reported by Cozza et 
al., who combined K137 inhibitor (N1-(4,5,6,7-tetrabromo-1H-benzimidazol-2-yl)-propane-1,3-diamine) with 
Glu4 tetrapeptide, highly improving both the affinity and selectivity towards CK233. In both cases, the design of 
inhibitors originated from a low-mass competitive inhibitor, to which acidic residues were linked without any 
broader sequence optimization.
Designing bi-substrate inhibitors by the independent optimization of the part targeting ATP-binding site, and 
peptides or peptidomimetics targeting substrate binding site may be a good alternative. In the broader view, this 
approach may be useful for designing generally bivalent inhibitors (i.e. inhibitors targeting two different sites of a 
protein, not necessarily substrate binding sites34) as there are already known some non-classic CK2 peptide-derived 
inhibitors that target the interface between the catalytic domain (CK2α) and the regulatory one (CK2β), i.e. 
CAM7117 with Kd = 150 nM35. There are also some CK2β motifs known to interact with other binding partners 
of CK236, so peptides or peptidomimetics interfering with these interactions may also be a promising alternative.
Herein, we propose a rational approach based on the independent screening for efficient ligands and peptides, 
both performed with thermodynamic methods, that score the ability of particular compounds to combine further 
into an efficient bi-substrate inhibitor. We present the first step of rational design of the bi-substrate inhibitor. We 
tested three libraries of peptides, originated from the known consensus sequence of CK2, to identify the optimal 
one with the highest affinity toward the catalytic subunit of human protein kinase CK2. We further verified the 
possibility of combining the developed peptides with an ATP-competitive ligand to form an efficient bi-substrate 
inhibitor, using tetrabromobenzotriazole (TBBt) as a model ATP-competitive inhibitor. Finally, we analyzed the 
inhibitory activity of an ad hoc synthesized bi-substrate ligand.
Results and Discussion
Peptide library screening against CK2. Peptides that efficiently bind to the target protein were selected using 
pull-down method with immobilized His-tagged catalytic subunit of human CK2 (CK2α), and further identified 
using liquid chromatography-mass spectrometry (LC-MS). Three peptide libraries were tested. The first one, [KGDE]-
[DE]-[ST]-[DE]3-NH2, contained 128 hexapeptides originating directly from the CK2 consensus sequence. The next 
library, containing 256 heptapeptides, was divided into two separate sub-libraries: [KGDE]-[DE]-[S]-[DE]4-NH2 and 
[KGDE]-[DE]-[T]-[DE]4-NH2, each consisting of 128 peptides. This approach was applied to overcome the substan-
tial difference in the efficiency of synthesis of threonine- and serine-containing peptides.
Signals identified in the MS spectra were assigned to a given peptide according to the indicated mass. 
However, this procedure led to several ambiguities, since a number of different peptides in the library displayed 
the same mass. LC-MS data was collected independently for the initial [KGDE]-[DE]-[ST]-[DE]3-NH2 library 
(Fig. 1a), and for the eluent released after passing this library through the column with immobilized hCK2α 
(Fig. 1b). Although in both runs the same peaks (i.e. M/z) were identified, their relative intensities visibly varied. 
We assumed that peptides displaying higher affinity to the protein should be enhanced in the second run. Some 
peptides were excluded from the further analysis due to their unspecific binding to the column’s resin (Fig. 1c). 
Finally, three peaks with substantially increased relative intensity in the eluent fraction were identified.
The first peak of 750 Da mass corresponds to an ensemble of six hexapeptides: EETEED-NH2, EETEDE-NH2, 
DETEEE-NH2, EETDEE-NH2, EDTEEE-NH2 and EESEEE-NH2, while the next two of 763 and 764 Da mass were 
identified as KETEEE-NH2 and EETEEE-NH2, respectively. The same procedure was performed for the two other 
libraries leading to the results consistent with those obtained for the first library (See Supplementary Figs S1, S2 
and Table 1S).
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Comparison of peptides identified in the pull-down assays pointed to favored peptides exhibiting two features: 
(1) glutamate residues flanking threonine/serine that undergo phosphorylation by CK2 (at most single aspar-
tate residue) and (2) the N-terminal lysine. Nine hexapeptides (EETEEE-NH2; KETEEE-NH2; EESEEE-NH2; 
KESEEE-NH2; EETEED-NH2; EETEDE-NH2; DETEEE-NH2; EETDEE-NH2; EDTEEE-NH2) were synthesized 
in a larger-scale and subjected to thermodynamic studies. DDTDDD-NH2 peptide was also used to compare the 
advantage of glutamic acid over the aspartic acid. Binding affinity to hCK2α for all of the above peptides was 
assessed semi-quantitatively, using relaxation-filtered NMR spectroscopy.
Transverse relaxation rate (R2), which reflects the efficiency of the spin-spin exchange mechanism, depends 
on the hydrodynamic properties of the molecule, in particular on its rotational diffusion in solution. The experi-
ment senses changes in 1H relaxation rates caused by the presence of hCK2α, binding to which decreases average 
rotational diffusion of the solute and thus almost uniformly affects relaxation rates of all 1H nuclei. In general, 
the transverse relaxation is much faster for larger molecules, whose nuclear spins experience much more effi-
cient exchange37,38. Dynamic properties of the peptide, when virtually bound to the protein, resemble those of 
its molecular target. Assuming a fast exchange between free peptide and low-populated protein-bound state, the 
apparent properties of the free peptide are affected by the contribution of the bound form to the overall nuclear 
relaxation, which visibly increases the efficiency of spin-spin exchange. Assuming that properties of the protein 
target do not vary significantly upon ligand binding, the stronger the peptide binding to its molecular target, the 
faster the transverse relaxation is.
To ensure that the observed effect was not associated with individual relaxation rates of free peptides in the 
solution, we performed a relaxation-filtered version of the experiment, with the relaxation delay varying in the 
range of 1 up to 200 ms. We observed substantial intensity variation of particular resonance lines caused by the 
increase of the delay, which were further quantitatively analyzed according to the model of two-exponential 
decay. The results of the analysis performed for the EETEED-NH2 peptide are shown in Fig. 2.
For each peptide we globally analyzed signals determined for the set of the representative 1H resonances (see 
methods), assuming that the faster relaxation rate (R2,f) corresponds to the relaxation processes averaged over free 
and bound states, thus revealing the population of molecules interacting with the target protein. The slower one 
(R2,s) describes the relaxation of molecules that did not sense the protein. The higher R2,f (or R2,f/R2,s ratio), the 
higher population of the peptide is bound, implying its stronger binding to the protein. The estimated relaxation 
rates are summarized in Table 1 and shown in Fig. 3.
All of the above data indicate that the KESEEE-NH2 peptide binds subtly stronger than any of the other tested 
peptides. Remaining peptides that do not carry the aspartic acid at position −2 relative to Ser/Thr bind to the 
hCK2α with comparable affinity, regardless the arrangement of further residues. Interestingly, Lys at position −2 
improves the affinity for peptide with serine at the acceptor site, while no such effect is observed for peptide with 
threonine. This may suggest that some tiny differences between binding of serine and threonine substrates take 
place, therefore allowing CK2 to discriminate them. The observed difference in binding of KESEEE-NH2 and 
EESEEE-NH2 must result from electrostatic interactions rather than from steric boundaries, since DESEEE-NH2 
binds to hCK2α with lower affinity. So, one may assume that the interaction pattern involving the first residue 
may depend on its type, and the preferred location of the N-terminal Glu may differ from that of Lys. This varia-
tion should be taken into account during the design of a linker to the low-mass ligand. Finally, DDTDDD-NH2, 
which corresponds to the C-terminal part of the commercially available reference peptide RRRDDDSDDD (used 
in the biochemical assays), binds visibly weaker to hCK2α.
Figure 1. Mass Spectra of [KGDE]-[DE]-[ST]-[DE]3 -NH2 library pull-down experiment (a) library (b) eluent 
of the library from immobilized His-tagged CK2α column (c) eluent of the library from column without CK2α 
(control).
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Determination of binding affinity. All peptides that were identified as strong binders in NMR 
relaxation-filtering experiments (i.e. those that do not carry Asp in the sequence) were further studied 
semi-quantitatively, with low volume differential scanning fluorimetry (nanoDSF). The representative thermal unfold-
ing profiles recorded for hCK2α in the presence of increasing concentration of KESEEE-NH2 are presented in Fig. 4.
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Figure 2. Relaxation-filtered NMR experiment for the EETEED-NH2 peptide in the presence of hCK2α. 
Ensemble of NMR spectra acquired with the increasing relaxation filter delay (a). Calculated intensity of 
different regions from NMR spectra in function of the relaxation filter delay (b).
Peptide R2,f (s−1) R2,s (s−1)
KESEEE-NH2 31.3 ± 7.8 2.5 ± 0.3
EETEEE-NH2 18.5 ± 3.1 3.1 ± 0.3
EESEEE-NH2 17.5 ± 2.8 2.3 ± 0.4
KETEEE-NH2 15.9 ± 1.3 2.6 ± 0.3
EETEED-NH2 16.1 ± 2.3 2.2 ± 0.5
EETDEE-NH2 15.4 ± 2.1 2.3 ± 0.5
DETEEE-NH2 10.4 ± 1.6 2.2 ± 0.6
EDTEEE-NH2 14.9 ± 2.5 1.5 ± 0.7
EETEDE-NH2 17.2 ± 4.8 3.7 ± 0.5
DDTDDD-NH2 7.1 ± 0.8 ~1
Table 1. Globally estimated relaxation rates for the free peptide (R2,s) and in the presence of hCK2α (R2,f).
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Figure 3. Transverse relaxation rates estimated for various protein-peptide complexes (R2,f),
5Scientific RepoRtS |         (2019) 9:11018  | https://doi.org/10.1038/s41598-019-47404-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Analogous experiments were performed for three other peptides (See Supplementary Fig. S3). All tested pep-
tides destabilize the protein, and for all of them the decrease of the melting temperature was found dependent 
on the peptide concentration. For the high-temperature region (i.e. T > 65 °C in Fig. 4) a minor dependence on 
peptide concentration is indicative of its unspecific binding to the unfolded form of the protein, while at the lower 
temperature binding of peptides causes a strong decrease of 350 nm/330 nm fluorescence intensity ratio. These 
changes were used to estimate the binding affinity at 25 °C, assuming the single binding site model. The same 
procedure was applied to the data collected at 75 °C. Interestingly, dissociation constants estimated at 25 °C and 
at 75 °C differ visibly (Kd for KESEEE- NH2 at 75 °C is ~1 mM and 0.35 mM at 25 °C), therefore indicating that 
peptides bind to both folded and unfolded state of hCK2α. It could be hypothesized that the destabilization of 
the protein at low peptide concentration may be caused by unfavorable entropy balance upon binding of such 
hydrophilic ligands.
The general order of peptides derived from nanoDSF is consistent with that obtained in the relaxation-filtered 
NMR experiments, confirming again that the binding affinity of KESEEE-NH2 is the highest (Table 2). The ther-
modynamic parameters of binding of KESEEE-NH2 peptide by hCK2α were also determined, with Microscale 
Thermophoresis, and further compared with the affinity of a commercially available reference peptide, 
RRRDDDSDDD (Table 2 and Fig. 5).
The peptide at concentration of approximately 1 mM causes hCK2a unfolding, which is manifested by the 
increase of fluorescence and distortion of raw MST data. This observation confirms the results obtained with nan-
oDSF, proving again that the peptide binds to the unfolded protein with Kd of about 1 mM. It should be empha-
sized that the binding affinity of KESEEE-NH2 towards hCK2α (Kd = 0.39 ± 0.21 mM) is significantly higher than 
that of commercially available RRRDDDSDDD peptide (2.1 ± 0.7 mM, ~1mM39).
Testing the cross-dependency of ligand and peptide binding. To verify the ability of the identified 
KESEEE-NH2 peptide to bind with a low-mass ligand and form an efficient bi-substrate inhibitor, the interactions 
between the peptide, protein and TBBt (model ligand that binds at the ATP-binding site) were monitored using 
three methods - ITC, MST and nanoDSF. Combination of these techniques allowed for determination of the for-
mal binding constant of peptide and ligand to the free protein, as well as peptide to ligand-protein complexes and 
ligand to peptide-protein complexes (Fig. 6 Table 2)
Comparison of peptide affinity towards the apo form of hCK2α and the hCK2α/TBBt complex was performed 
using nanoDSF and MST. Both methods confirmed that the presence of TBBt does not significantly affect peptide 
binding. The same applies to the KESEEE-NH2 interference with the TBBt binding, which effect was studied with 
ITC and MST. The corresponding values of dissociation constant remain the same within the experimental error. 
It could be thus concluded that the presence of peptide does not change the TBBt affinity, so both of them can be 
used as templates for designing a bi-substrate inhibitor.
Molecular modeling of bi-substrate inhibitor. Molecular modeling of the ternary complex of hCK2α, 
TBBt, and EESEEE-NH2 or KESEEE-NH2 peptide was performed by a combination of modeling by homology 
with iterative modification of the ligand peptide followed by restrained molecular dynamics. The final structure 
of both complexes was found stable in terms of 30 ns unrestrained molecular dynamics (Fig. 7). The location 
of KESEEE-NH2 is stabilized by electrostatic interactions formed with proximal side-chains of Arg47, Lys49, 
Lys74, Lys76, Lys77, Lys158, His160, Arg191 and Lys198. All these interactions contribute to the stabilization 
of protein-peptide, which was estimated with FoldX to 4.2 kcal/mol. The in silico determined kd = ~0.8 mM is 
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Figure 4. Thermal denaturation profile of KESEEE-NH2-hCK2α complex monitored as 350 nm/330 nm 
fluorescence ratio recorded at the increasing KESEEE-NH2 peptide concentration (from the lowest – yellow, 
to the highest – brown). For clarity, all curves were aligned at the high-temperature asymptotes. Nested graph 
summarizes changes in the fluorescence at 25 °C as a function of KESEEE-NH2 concentration.
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therefore close to the value of 0.3 +/− 0.2 mM determined experimentally with MST. It is worth noting that the 
side-chain nitrogen of the N-terminal lysine of the peptide points towards TBBt, located at the ATP binding site, 
thus directing the way for setting up a bi-substrate ligand. The same procedure was applied for the EESEEE-NH2 
peptide. In this case, the side-chain of the N-terminal residue was preferably oriented away from TBBt, there-
fore disqualifying side-chain of the N-terminal Glu as a potential linker, which could be however linked via the 
N-terminal amino group. Importantly, the complex with KESEEE-NH2 remained in the open conformation, 
while that with EESEEE-NH2 has switched to the closed one.
Potency of bi-substrate inhibitor against human CK2α. To confirm the validity of our approach, 
we synthesized ad hoc a simple, bi-substrate compound, based on the optimized peptide sequence, that was 
conjugated by an amide bond formed between side chain of the N-terminal lysine and 7-COOH-Br3Bt. The 
inhibitory activity of this preliminary bi-substrate inhibitor, IC50 = 0.67 ± 0.15 µM, is comparable to that of 
TBBt (0.62 ± 0.28 µM), but higher than that of the leading 7-COOH-Br3Bt (8.0 ± 6.3 µM). Therefore, when com-
pared with the affinity of the low-mass precursor, we obtained over 10-fold enhancement of inhibitory activity 
for bi-substrate ligand, while coupling of Glu4 with K137 improved the inhibitory activity only 5-fold33). This 
clearly exemplifies the potency of the proposed approach, proving the importance of the optimization of peptide 
sequence. However, taking into account IC50 values reported for CK2 bi-substrate inhibitors K137-E4 and ARC-
1502 (25 nM33 and 2.7 nM30, respectively), it is clearly understandable that the low-mass ligand as well as the 
linker must be further optimized.
titrate
nanoDSF
hCK2α hCK2α + TBBt
titrant KESEEE-NH2 EESEEE-NH2 KETEEE-NH2 EETEEE-NH2 KESEEE-NH2
Kd(mM) 0.35 ± 0.02 1.58 ± 0.06 0.95 ± 0.05 0.96 ± 0.03 0.45 ± 0.02
ΔG (kJ/mol) −19.73 ± 0.14 −15.99 ± 0.09 −17.25 ± 0.13 −17.23 ± 0.08 −19.10 ± 0.11
titrate
MST
hCK2α hCK2α + KESEEE-NH2 hCK2α + TBBt
titrant KESEEE-NH2 RRRDDDSDDD TBBt KESEEE-NH2
Kd(mM) 0.39 ± 0.21 2.1 ± 0.7 (96 ± 44)∙10−6 (86 ± 28)∙10−6 0.36 ± 0.23
ΔG (kJ/mol) −19.5 ± 1.3 −15.3 ± 0.8 −40.1 ± 1.1 −40.3 ± 0.8 −19.7 ± 1.6
titrate
ITC
TBBt TBBt
titrant hCK2α hCK2α + KESEEE
Kd(µM) 0.06 ± 0.03 0.10 ± 0.07
ΔG (kJ/mol) −41.3 ± 1.1 −40.0 ± 1.6
ΔH (kJ/mol) −25.1 ± 1.2 −17.7 ± 1.7
ΔS (J/mol/K) 47 ± 8 70 ± 11
Table 2. nanoDSF-, MST- and ITC-derived thermodynamic parameters of binding of the peptides and TBBt to 
hCK2α, separately and for their ternary complexes.
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Figure 5. Microscale thermophoresis (MST) data for binding of: KESEEE-NH2 (diamonds) and commercially 
available peptide – RRRDDDSDDD (circles) to hCK2α.
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conclusions
In this work we presented a rationalized approach in CK2 drug design, in which the peptide part of a bi-substrate 
inhibitor was optimized to obtain an effective bi-substrate inhibitor. Combining experimental thermodynamic 
methods, we successfully screened three peptide libraries and identified the KESEEE-NH2 hexapeptide that binds 
to hCK2α with affinity higher than any of the studied peptides previously used as substrates for this kinase. We 
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Figure 6. Ternary system analysis. MST data for binding of: (a) KESEEE-NH2 to hCK2α (left panel) and to 
TBBt/hCK2α complex (right panel) (c) tetrabromobenzotriazole to hCK2α (left panel) and KESEEE-NH2/
hCK2α complex (right panel). (b) nanoDSF data for binding of KESEEE-NH2 to hCK2α (left panel) and to 
TBBt/hCK2α complex (right panel). (d) ITC data for TBBt binding to hCK2α (left panel) and to KESEEE-NH2/
hCK2α complex (right panel).
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also proved that the binding of this peptide does not significantly attenuate the binding of an ATP-competitive 
ligand, which makes the proposed peptide a promising part of an efficient bi-substrate inhibitor. Molecular mod-
eling additionally supports this hypothesis, clearly demonstrating that the linking of halogenated benzotriazole 
with the N-terminal lysine of the peptide may form an efficient bi-substrate ligand. In summary, the presented 
experimental approach supports the rational design of specific bi-substrate inhibitors of CK2, which also can be 
applied to other protein kinases.
Methods
Expression and purification of hCK2α. The catalytic subunit of human CK2, hCK2α, was expressed and 
purified according to the method described previously40.
Peptide library synthesis. Three peptide libraries [KGDE]-[DE]-[ST]-[DE]3-NH2, [KGDE]-[DE]-[S]-
[DE]4-NH2 and [KGDE]-[DE]-[T]-[DE]4-NH2 were synthesized by standard solid-phase peptide synthesis on 
TentaGel S RAM resin (Rapp polymere) using a Prelude peptide synthesizer (Protein technologies) with equimo-
lar peptide building blocks. Side chain protecting groups were Boc, tBu and OtBu for Lys, Ser/Thr and Asp/Glu 
respectively. Cleavage was performed with 95:2.5:2.5% trifluoroacetic acid (TFA):triisopropylsilane:H2O, and the 
resulting peptides were precipitated with cold diethyl ether, centrifuged, the pellets were then dissolved in H2O 
and finally lyophilized. The compositions of libraries were analyzed by ESI-MS41. To avoid losing single peptides, 
the products were purified by dialysis against TBS buffer (25 mM Tris-HCl, 0.15 M NaCl, pH 7) and verified by 
ESI-MS using LC-MS separation on RP-C18 resin.
peptide synthesis. 10 Peptides: EETEEE-NH2; KETEEE-NH2; EESEEE-NH2; KESEEE-NH2; EETEED-NH2; 
EETEDE-NH2; DETEEE-NH2; EETDEE-NH2; EDTEEE-NH2 and DDTDDD-NH2 were synthesized as 
described above. The products were purified by HPLC using Empower system (Waters) equipped with RP-amide 
semi-preparative column (5 µm particle size, 250 × 10 mm) (Ascentis). The mobile phase consisted of (A) 0.1% 
TFA in water and (B) 0.1% TFA with 90% acetonitrile in water. The purity and identity of lyophilized peptides was 
verified by ESI-MS using LC-MS separation. The final concentration was determined using Direct Detect Infrared 
Spectrometer (Merck).
Bi-substrate inhibitor synthesis. 4,5,6-tribromo-7-methyl-1H-benzotriazole (7-CH3-Br3Bt) (1) was 
obtained in good yield, according to the previously published procedure42. Subsequent oxidation with KMnO4 
led to 7-COOH-Br3Bt (2) in 22% yield and high purity (see supplementary Fig. S4).
Bi-substrate inhibitor was synthesized and purified the same way as peptides described above, with 
7-COOH-Br3Bt (2) as the first residue in sequence. The purity and identity of lyophilized compounds was verified 
by ESI-MS using LC-MS separation.
pull-down assays. Pull-down assays were used to identify peptides that strongly interact with CK2. For this 
purpose the Pierce™ His Protein Interaction Pull-Down Kit was used. Protein diluted in TBS buffer was incu-
bated with cobalt resin supplemented in Kit (initially equilibrated with TBS buffer) at 4 °C for 1 h with continuous 
mixing. The resin was separated by centrifugation and the supernatant was removed. The resin was then washed 
Figure 7. Snapshots of the Molecular Dynamic trajectory performed for the ternary complex of hCK2α and 
TBBt with KESEEE-NH2 (a) and with EESEEE-NH2 (b). The peptide backbone is denoted in magenta with the 
N-terminal Lys/Glu residue in ball-and-stick representation.
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five times with TBS buffer. Next, TBS buffer containing peptide library was added and incubated overnight at 4 °C 
with continuous mixing. To separate peptides that efficiently bind to the protein, the resin was centrifuged and 
washed two times with TBS buffer. Material bound to the column was eluted with 2 M glycine pH 2.5 and further 
identified by ESI-MS separation on RP-18 resin.
Relaxation-filtered NMR spectroscopy. NMR samples containing tested peptides and hCk2α were pre-
pared in 25 mM Tris–HCl (pH 7, 0.25 M NaCl) buffer with 10% D2O. The protein concentration was 25 μM, and 
a 100-fold peptide excess (2.5 mM) was used throughout the studies.
The scoring of the peptides’ binding affinities towards hCK2α was done according to the results of 1H trans-
verse (T2) relaxation filtering experiment43. All spectra were recorded at 25 °C on Bruker Avance 500 NMR spec-
trometer (11.7 T) using 18 delays (0, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150 and 200 ms). The spectra 
of 7500 Hz spectral width, 16k data points each, were collected using 16 scans with 2.0 s recycling delay preceded 
by 8 dummy scans.
NMR data were further processed and analyzed with the SpinWorks software (version 4.2.8.0), using 
cosine-squared window function and Gaussian filter resulting in 0.3 Hz broadening with no solvent filter applied 
prior to Fourier transformation. We analyzed 1H transverse relaxation rates of selected nuclei representative for 
each type of amino acid residues present in the tested peptides, i.e Hγ of Glu (2.3ppm), Hβ of Asp (2.8ppm), Hβ 
of Ser (3.8ppm), Hγ(CH3) of Thr (1.1 ppm) and Hε of Lys (2.9ppm), respectively. Additionally, the resonance 
signals of amide protons (8.2–8.9ppm) were also analyzed. We performed the relaxation-filtered experiment, with 
the relaxation delay varying in the range of 1 to 200 ms. Variation in the intensity of particular resonance signals 
were analyzed using the model of two-exponential decay (1):
= ⋅ ∗ + ⋅ ∗ +y A t R A t R yexp( ) 2 exp( ) (1)f s1 2, 2, 0
where R2,s and R2,f are the transverse relaxation rates of the free and the fraction of the virtually bound peptide, 
respectively. For each peptide the global optimization procedure was applied for all identified resonance signals.
Low-volume screening with differential scanning fluorimetry (nanoDSF). The assay was carried 
out in 25 mM Tris–HCl (pH 7, 0.5 M NaCl) buffer with protein concentration preserved constant at 2.5 μM, 
while peptide concentrations varied in the 300 nM-10 mM range. The samples were loaded into nanoDSF Grade 
Standard Capillaries (NanoTemper Technologies), and analyzed using the Prometheus NT.48 nanoDSF device 
(NanoTemper Technologies). Thermal unfolding of the protein was monitored using a linear thermal ramp (1 °C/
min; 20 °C to 80 °C) with an excitation power of 30%. Binding affinity of peptides was estimated from the ratio 
of 330 nm and 350 nm estimated at 25 °C and 75 °C for the native and unfolded forms of the protein, respectively. 
The data was analyzed using the numerical model implemented in Origin 9.0 package (www.originlab.com).
Microscale Thermophoresis (MST). The hCK2α sample was initially labeled with the commercially avail-
able NT-647 dye, using NanoTemper Protein Labeling Kit RED. The concentration of the ligand varied in the 
range of 100 nM-10 mM, while the concentration of the labeled protein was kept constant at 50 nM. All obtained 
data were analyzed according to the method described previously44, using appropriate model implemented in 
Origin 9.0 (www.originlab.com). Dissociation constants were estimated globally for a series of three independent 
pseudo-titration MST experiments, using effect of thermophoresis with temperature jump as the reporter of 
protein-ligand interaction.
Isothermal titration calorimetry (ITC). All ITC measurements were carried out at 25 °C with the Nano 
ITC calorimeter (TA Instruments), using 250 rpm stirring and 1000 s delay between succeeding injections to the 
sample cell of the volume 950 μl. The 12 injections of 20 μl volume following first pre-injection of a reduced vol-
ume (4 μl) were analyzed. The sample cell was initially filled with 4–10 μM TBBt solution, while 20–60 μM protein 
solution was placed in the syringe. Ternary complex formation was tested using the same experimental setup 
with the tested peptide present both in the cell and in the syringe at identical concentration of 500 μM. For each 
protein/ligand combination at least two titration experiments were done with different reagent concentrations. 
The data were further processed using the numerical model implemented in Origin 9.0 package (www.originlab.
com), assuming existence of one type of binding sites of the apparent stoichiometry close to 1:1.
Molecular modeling. Initial structure of the ternary complex of hCK2α with TBBt and KDS tripeptide 
was adopted from the accessible structures of TBBt bound to the catalytic subunit of maize CK2 (pdb1J91)45 and 
kinase Pim-1 with its substrate peptide (pdb3MA3)22. After replacement of the last three residues by a required 
sequence KES, the resulting structure was optimized and further relaxed with 5 ns molecular dynamics in the 
NPT ensemble, in the presence of explicit water molecules, with coordinates of protein backbone and serine of the 
ligand peptide constrained. In the successive steps, three Glu residues were added one-by-one at the C-terminus 
of the peptide, and each of these structures were successively subjected to 5 ns constrained MD, in which various 
distance restraints were tested to facilitate formation of salt-bridges with proximal basic residues of hCK2α. The 
final model of the ternary complex hCK2α/TBBt/KESEEE-NH2 was further subjected to 50 ns unrestrained MD 
performed in the NTP ensemble (298 K, 1 atm). The structure of the ternary complex hCK2α/TBBt/EESEEE-NH2 
was adopted from that with KESEEE-NH2, and further subjected to 30 ns unrestrained molecular dynamics. All 
calculations were performed with Yasara Structure using Yasara2 force-field.
In vitro inhibitory activity towards human CK2α. The ADP-Glo kinase assay (Promega) was used 
to measure the inhibition effect of the tested compounds. The kinase assay was carried in 96-well plate in vol-
ume of 25 μl in 20 mM Tris–HCl (pH 7.5) buffer, containing 100 ng hCK2α (1 μl), 10 μM CK2 substrate peptide 
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RRRDDDSDDD (Biaffin GmbH & Co KG), 10 μM ATP, 20 mM MgCl2 and 2.5 μl of serially diluted ligand in 
DMSO. The reaction was initiated with enzyme in and kept going for 20 min at 30 °C. Reaction was stopped by 
adding 25 μl of ADP-Glo reagent. After incubation at room temperature for 40 min (to consume the remaining 
ADP) 50 μl of kinase detection reagent were added and incubated for additional 30 minutes to produce lumines-
cence signal. Luminescence was measured with The SpectraMax iD3 Multi-Mode Microplate Reader (Molecular 
Devices). IC50 values were determined using three independent experiments, 7 inhibitor concentrations in the 
range of 1nM-1mM each, by global fitting of the sigmoidal dose-response equation implemented in Origin 9.0 
package (www.originlab.com). Single experiment was analyzed for TBBt to confirm agreement with already pub-
lished data42,46,47.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on a reasonable request.
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